NIIMBL is preparing to launch the Viral Vector Manufacturing and Analytics Program.
NIIMBL is well-positioned to bring together the appropriate resources to accelerate development of core manufacturing process platforms and essential analytical capabilities for viral vector product and process characterization. These processes can be used to develop a shared understanding in discussions with health authorities, support activities of the Bespoke Gene Therapy Consortium and be used as a platform for innovating new technologies. The initial focus of the program will be on AAV-based vectors for gene therapy.
